A phase I clinical study of ENA-001 for stimulation of ventilation in respiratory depression associated with drug overdose.
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs ENA-001 (Primary) ; ENA-001 (Primary)
- Indications Respiratory insufficiency
- Focus Adverse reactions
- 24 Jan 2025 New trial record
- 24 Sep 2024 According to a Enalare Therapeutics media release, Company announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I clinical study in the United States with ENA-001, that supports the proposed indication for stimulation of ventilation in respiratory depression associated with drug overdose.